Chemotherapy Dose Delay Interpreter
Chemotherapy Dose Delay Interpreter
There is no universal neutrophil or platelet threshold for giving chemotherapy, and a page that printed one as though there were would be worse than no page. The thresholds are written into each regimen’s own protocol, they differ between regimens and between trials, and the commonly used figures are convention rather than evidence. What this page does is state the convention honestly, show where it comes from, and set out the decisions that sit around it — including the one about dose intensity that matters more than the threshold does.
Hold the cycle, reduce the dose, or proceed?
Counts + context → hold, reduce or proceedA patient on adjuvant FOLFOX attends for cycle 5. The neutrophil count is 1.1 × 10⁹/L and the platelet count is 88 × 10⁹/L. Cycle 4 was delayed a week for the same reason. No granulocyte colony-stimulating factor is being given, the protocol’s own threshold table is not to hand, and the Duffy status is not known.
What the thresholds are, and what they are not
These are convention, not guideline. No major body publishes a general threshold, because the right figure depends on the regimen’s expected nadir, the treatment intent, the growth factor support in place and the patient. One published series found that solid tumour patients treated with a neutrophil count between 1.0 and 1.5 × 10⁹/L did not do worse for fever, antibiotic use, hospitalisation or subsequent delay, and noted that there is no clear evidence for the cut-off in use.
The treating protocol overrides everything on this page. Where it states thresholds, use those and record which version you applied.
Worked example
A patient on adjuvant FOLFOX attends for cycle 5. The neutrophil count is 1.1 × 10⁹/L and the platelet count is 88 × 10⁹/L. Cycle 4 was delayed a week for the same reason. No granulocyte colony-stimulating factor is being given, the protocol's own threshold table is not to hand, and the Duffy status is not known.
The protocol's thresholds are not available, so the conventional figures apply as a documented default — and the entry to make in the notes is that they were used as a default
Duffy status not known, so the Duffy-null route does not apply. Worth asking, though: if this patient's neutrophil count has always sat near 1.2 rather than having fallen to it, the threshold is the wrong comparator
1.1 is not below 0.5 and 88 is not below 25 — so neither is grade 4 and neither is an emergency
1.1 is not below 1.0, and 88 is not below 75 — so neither count is below the firmer of the two conventions
1.1 is below 1.5 and 88 is below 100 → both are short of the common convention. Hold, recheck in about a week
The more important finding is the pattern. This is the second consecutive cycle delayed for the same reason in an adjuvant regimen. The recommended response to a recurring neutropenic event on a regimen without growth factor support is secondary prophylaxis with G-CSF rather than a dose reduction, precisely because reducing the dose might compromise the outcome
Change one entry and the emphasis changes. Make the intent palliative and the same two delays argue for a planned dose reduction instead, because dose intensity is not the objective there
Where the numbers on this page come from
| Figure | Status | What it rests on |
|---|---|---|
| Neutrophils 1.5 × 10⁹/L to proceed | Convention | In very wide use and written into many protocols. Examined in print and found to lack clear evidence; patients treated between 1.0 and 1.5 did not fare worse in one reported series |
| Platelets 100 × 10⁹/L to proceed | Convention | Common, but many regimens use 75 instead, and some vary it by drug within one regimen |
| Neutrophils below 0.5, platelets below 25 | Grading, not a threshold | CTCAE v5.0 grade 4. No regimen proceeds here, but the grade is an adverse event classification rather than a treatment rule |
| G-CSF primary prophylaxis at about 20% febrile neutropenia risk | Guideline | ASCO recommendation, with consideration at lower risk where patient factors add to it |
| G-CSF secondary prophylaxis after an event | Guideline | ASCO recommendation where a dose reduction or delay would compromise outcome — that is, in curative and adjuvant treatment |
| A replacement threshold for Duffy-null patients | Does not exist | ASH recommends integrating Duffy testing into trials to generate the data. No number has been published, and none is offered here |
Delay, reduce, or support — what each one costs
| Response | What it protects | What it costs | When it is the right answer |
|---|---|---|---|
| Delay the cycle | Safety this week | Dose intensity, quietly and cumulatively | A first event, or a count that will clearly recover within days |
| Reduce the dose | Tolerability across the remaining cycles | Dose intensity, permanently and explicitly | Palliative intent; cumulative thrombocytopenia; recurrent events despite support |
| Add growth factor support | Dose intensity | Cost, bone pain, and a small risk of its own | Curative or adjuvant intent with a recurring neutropenic event — the guideline answer |
| Change the regimen | Both, potentially | Efficacy, if the alternative is less effective | Recurrent events despite support, or a toxicity that is not haematological |
Why there is no universal threshold, and what to do about it
Ask three oncology departments what neutrophil count a cycle of chemotherapy requires and you will get three answers, all of them defensible. The figure most often quoted is 1.5 × 10⁹/L, with platelets at 100 × 10⁹/L or sometimes 75. None of that comes from a guideline. No major body publishes a general haematological threshold for administering chemotherapy, and the reason is that a general threshold would have to ignore everything that determines whether it is safe: what the regimen’s expected nadir is, how fast it recovers, whether growth factor support is in place, whether the intent is cure or control, and what the individual patient’s marrow has done in previous cycles.
The 1.5 figure has been examined directly, and it has not held up as well as its ubiquity suggests. A reported series of solid tumour patients treated with neutrophil counts between 1.0 and 1.5 × 10⁹/L found no significant difference in fever, antibiotic use, hospitalisation or subsequent treatment delay compared with patients treated at higher counts, and the authors noted plainly that there is no clear evidence for what the cut-off should be. That is not an argument for ignoring the convention. It is an argument for recognising what it is: a reasonable default where the protocol is silent, and a decision to be documented rather than a rule to be obeyed.
What the literature does support strongly is the decision that sits behind the threshold. In curative and adjuvant treatment, the dose delivered over the planned time is part of the treatment effect, and it erodes through exactly the mechanism this page describes — a week’s delay, then another, then a reduction that never gets reversed. The ASCO recommendations on white blood cell growth factors are explicit about the ordering: primary prophylaxis where the regimen carries a febrile neutropenia risk of about 20 per cent or more, and secondary prophylaxis after an event when a dose reduction or delay would compromise the outcome. In other words, support the dose before reducing it. In the palliative setting the trade runs the other way and a reduction that improves tolerability is often the better decision.
One group is served particularly badly by a fixed threshold. People of African or Middle Eastern ancestry with the Duffy-null phenotype have a constitutionally lower circulating neutrophil count with a normal marrow reserve and no increased risk of infection, and the reference intervals and treatment thresholds in use were derived from populations in which that phenotype was under-represented. The result is that a normal variant is read as a cytopenia and treatment is withheld or trials are closed off. There is no published replacement number, and this page does not invent one — the American Society of Hematology’s position is that Duffy testing should be built into trials in order to generate the data, which is an acknowledgement that the number does not yet exist. What can be done now is to use the patient’s own stable baseline as the comparator rather than the population threshold, and to say so in the notes.
Frequently asked questions
What neutrophil count do I need to give chemotherapy?
Whatever the treating protocol says. Where the protocol states thresholds, they govern, and they differ between regimens because the expected nadir and recovery differ. Where it is silent, the convention in widest use is a neutrophil count of at least 1.5 × 10⁹/L and a platelet count of at least 100 × 10⁹/L, with 75 used for platelets in many regimens. Those figures are convention rather than guideline, and applying them where a protocol is silent should be recorded as a documented default.
Is the 1.5 × 10⁹/L threshold evidence-based?
Not strongly. It is in very wide use and is written into many protocols, but no guideline publishes it as a general rule, and it has been examined directly: a reported series of solid tumour patients treated with counts between 1.0 and 1.5 × 10⁹/L found no significant difference in fever, antibiotic use, hospitalisation or subsequent delay, with the authors noting that there is no clear evidence for the cut-off that should be used. Treat it as a sensible default, not as a fact.
My patient keeps being delayed for neutropenia. Should I reduce the dose?
In curative or adjuvant treatment, usually not as the first move. The ASCO recommendation is secondary prophylaxis with a granulocyte colony-stimulating factor after a neutropenic event on a regimen given without it, specifically where reducing the dose or delaying the cycle might compromise the outcome — that is, support the dose before reducing it. If events recur despite growth factor support, then a dose modification or a change of regimen is appropriate, and it is worth looking for a contributing cause such as marrow involvement, a second myelosuppressive drug, or a nutritional deficiency. In palliative treatment, a dose reduction is often the better trade from the start.
What about a patient with a constitutionally low neutrophil count?
The Duffy-null associated neutrophil count is a normal variant, common in people of African and Middle Eastern ancestry, with a normal marrow reserve and no increased risk of infection. Conventional thresholds were not derived in populations where it was well represented, so applying them withholds treatment for something that is not a cytopenia. There is no published replacement threshold — ASH recommends building Duffy testing into trials to generate the data — so use the patient’s own stable baseline as the comparator, document the reasoning, and involve the treating consultant. Duffy-null status does not protect against genuine chemotherapy-induced suppression, so a substantial fall from that baseline is still a real fall.
Does a low platelet count get treated the same way as a low neutrophil count?
No, and the difference matters. Platelet recovery is slower, so rechecking at a week is more realistic than at three days. Several drugs — carboplatin, gemcitabine, the nitrosoureas — are cumulatively thrombocytopenic, producing a nadir that is lower and a recovery that is later with each cycle, and that pattern calls for a planned dose reduction rather than a series of unacknowledged delays. There is also no growth factor equivalent in routine use for platelets. And always confirm that a low count is real: platelet clumping and EDTA-dependent pseudothrombocytopenia have both delayed cycles unnecessarily, and repeating the sample in citrate excludes the latter.
Related calculators
References
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-3212.
- Souto Moura T, et al. Safety of chemotherapy recycling in solid tumour patients with an absolute neutrophil count under 1500/mm3. Ann Oncol. 2014;25(suppl 4):iv526 [conference abstract].
- Merz LE, Achebe M, et al. Cancer trial eligibility and therapy modifications for individuals with Duffy null-associated neutrophil count. JAMA Netw Open. 2024;7(9):e2432475.
- American Society of Hematology. Duffy-null Associated Neutrophil Count (DANC) — reconsideration of absolute neutrophil count reference ranges by Duffy status. Accessed 2026.
- US Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Published 27 November 2017.
- Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(14):1443-1453.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.